Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024

Mar 28 2024

• By Joseph Haas

Eye — Aldeyra will launch new Phase III study in dry eye to respond to FDA CRL

Related Content

Dry Eye Crossover Study Could Allow Aldeyra A Quick Response To US FDA’s CRL For Reproxalap

Nov 29 2023

Aldeyra Plans Quick Response To FDA’s CRL For Reproxalap

Nov 28 2023

Deal Watch: Graphite Exits Via Reverse Merger With Presbyopia Specialist LENZ

Nov 16 2023

Aldeyra Looking At Paths To Approval In Dry Eye After Phase III Miss

Dec 22 2021

Aldeyra Therapeutics Eyes First Line Market As Phase II Dry Eye Candidate Impresses

Jan 12 2022

Related Companies

Aldeyra Therapeutics, Inc.

AbbVie Inc.

Additional Topics

Clinical Trials Drug Approval Standards Business Strategies Research & Development Ophthalmic BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window